Lorenzo D'Angelo

Lorenzo D'Angelo | Life Sciences | Charles River Associates

Lorenzo D’Angelo is a principal in the Life Sciences Practice of CRA. He has considerable experience consulting with global pharmaceutical and medical device companies on their commercial and medical affairs strategies.

Lorenzo has supported clients in taking strategic decisions as well as implementing them along the product lifecycle: assessing new and growth opportunities, developing go-to-market and launch strategies, as well as strategies for medical affairs. In these projects he leverages his multiple years of experience in collaborative scientific/industrial research, project management, market research, and analytical and statistical methodologies. In recent work he supervised projects to understand customer segments and sentiment, generating evidence and guidance as well as leveraging opportunities in digital health. His work is focused on Europe and the US but includes other growing markets in Asia, Latin America, and beyond.

Prior to joining CRA, Lorenzo was a research group leader at TU München. He has participated in scientific conferences around the world and has published book chapters and articles in academic journals. His background in medical device engineering drives him to find new solutions in life sciences that can go from lab development to market launch and beyond.

Selected engagements

  • 01
    Evidence generation for a virtual 3D surgical planning software
    A leading MedTech company sought to demonstrate the unique benefits of their virtual 3D surgical planning software in thoracic surgery, as opposed to the...
    View engagement
  • 02
    A unified patient flow model to prioritize opportunities
    CRA approach: Developed, together with the client’s global teams, disease-specific patient flow models  Conducted live patient flow and findings workshops...
    View engagement
  • 03
    Showcasing the value and revenue potential of an asset in development
    A Biotech company sought to quantify the revenue potential and develop a forecast model for their asset, which is currently in early clinical development – the...
    View engagement